The Rx Recap: June 29-July 4

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer

OncLive informed readers that intraperitoneal IMNN-001, an IL-12–directed gene therapy, showed promise in the frontline treatment of advanced epithelial ovarian cancer in the phase I/II OVATION-2 trial. When combined with standard chemotherapy, IMNN-001 improved median progression-free survival (14.9 vs 11.9 months) and overall survival (46.0 vs 33.0 months) compared with chemotherapy alone. Unlike prior intravenous IL-12 therapies, the localized delivery reduced systemic side effects while effectively stimulating the immune response. These encouraging results have led to the phase 3 OVATION-3 trial to confirm efficacy and explore maintenance strategies.

3D mammogram use boosted by removing out-of-pocket fee

Eliminating a $45 out-of-pocket fee significantly increased patient access to digital breast tomosynthesis (DBT), according to a study in JACR covered by Contemporary OBGYN. DBT usage rose from 83.7% to 91.5% after the fee was removed, with the greatest increases seen among Asian, Black, Hispanic, and non-English-speaking patients. Researchers noted that while removing financial barriers improved access and reduced disparities, further efforts are needed to fully achieve equity in breast cancer screening.

FDA clears first AI-driven wristband for essential tremor relief

Medical Economics told readers the FDA has granted 510(k) clearance to the Felix NeuroAI Wristband, the first noninvasive, AI-powered device approved for reducing tremor-related limitations in adults with essential tremor. Developed by Fasikl, the wristband delivers personalized, adaptive stimulation throughout the day via a cloud-connected platform—eliminating the need for drugs or surgery. Clinical trial data from the TRANQUIL study showed significant tremor reduction and improved daily function with no serious adverse effects. As wearable neuromodulation advances, this approval marks a major milestone in noninvasive, AI-driven treatment options for movement disorders.

FDA Removes REMS for Currently Approved BCMA-, CD19-Directed CAR T Cell Immunotherapies

The FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for all currently approved BCMA- and CD19-directed autologous CAR T-cell therapies, citing increased provider experience and no ongoing need to ensure benefit-risk balance. Previously, Pharmacy Times stated REMS required institutions to be certified and maintain on-site access to tocilizumab for managing severe side effects like cytokine release syndrome and neurotoxicity. While these risks remain, the FDA emphasized that proper product labeling and ongoing safety monitoring will continue. The change is expected to reduce provider burden and improve patient access to these potentially curative therapies.

Botanical nootropics and how they’re shaping the future of cognitive health innovation

As interest in cognitive health grows, Nutritional Outlook stated consumers are increasingly turning to botanical nootropics—natural ingredients like ginkgo biloba, bacopa monnieri, lion’s mane mushroom, and huperzine A—for mental clarity and brain support. Once niche, these plant- and fungi-derived ingredients are now central to cognitive wellness formulations. However, creating credible products requires clinical validation, responsible sourcing, and compliant marketing. Experts urge brands to use standardized extracts, ensure ingredient transparency, and follow FDA guidelines when making cognitive claims. With a focus on science, quality, and education, natural nootropics offer a promising path for innovation in brain health.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.